Retina

FDA approves biosimilar to Lucentis

The US Food and Drug Administration has approved ranibizumab-nuna (Byooviz), a biosimilar to ranibizumab (Lucentis), for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV), according to a company press release. This is the first ophthalmology biosimilar approved in...